RODRICK SPADINGER - CYSTIC FIBROSIS ADVOCATE
Born and raised in Honolulu, Hawaii, I have used my quest for education and knowledge for both professional advancement and personal growth. Having earned an MBA from DePaul University, I furthered my career in the banking field, focusing primarily on the small business community in Hawaii. Recently, it has become a focus of mine to reach out to those of us who are affected by cystic fibrosis through the start of a blog to address advancements and treatments for this genetic and fatal lung disease. Thanks for reading my postings!
Read More »
...
- Page Views
- 1,215
- Content
- 8
- Fans
- 0
- Contributor since
- 8/7/2011
Education/Experience
BBA in Accounting, BBA in Finance - University of Hawaii at Manoa, MBA in International Marketing and Finance - DePaul UniversityAffiliations
Our CF Matters HawaiiFavorites
None yet.Fans
None yet.
Displaying Results 1 - 8 (of 8) for All Content
-
Origin of the Cystic Fibrosis Sweat TestPrior to the 1950s, there was no definitive test to determine whether a child was suffering from cystic fibrosis. This changed with the development of what is now considered to be the gold standard in CF diagnostic tests, the sweat test, in the 1950s.
-
Tobramycin Inhalation Powder - Potential Cystic Fibrosis DrugTOBI, a tobramycin inhaled solution, was approved by the U.S. FDA in 1997 as an inhaled version of the antibiotic tobramycin to treat CF patients. As an alternative to TOBI, Tobramycin Inhalation Powder is currently being studied in clinical trials.
-
Results of the Potential Cystic Fibrosis Drug VX-770 Phase 2 Clinical Trial DISCOVERResults from one of the three legs of a clinical study for the potential next generation drug VX-770 designed to treat the chronic and fatal lung disease Cystic Fibrosis were announced in February 2011.
-
Results of the Potential Cystic Fibrosis Drug VX-770 Phase 3 Clinical Trials STRIVE and ENVISIONResults from two of the three legs of a Phase 3 clinical study for the potential next generation drug VX-770 designed to treat the chronic and fatal lung disease Cystic Fibrosis were announced in June 2011.
-
VX-661: Potential Cystic Fibrosis DrugVX-661 is one of the new generation of potential Cystic Fibrosis drugs that is currently being tested to treat this fatal lung disease.
-
The Cause of Cystic Fibrosis - the CFTR GeneThe CFTR gene is recognized as the cause of the chronic disease cystic fibrosis, which affects approximately 30,000 individuals in the United States, and 70,000 worldwide.
-
Ataluren Phase 2a Clinical Trial Results for Treatment of Cystic FibrosisPhase 2a clinical trial results on Ataluren, one of the several potential Cystic Fibrosis drugs in development.
-
Cystic Fibrosis Timeline: 1930sA brief view of how the disease "cystic fibrosis" was first termed and discovered in the 1930s.